Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate

This study has been completed.
Sponsor:
Information provided by:
Merz Pharmaceuticals GmbH
ClinicalTrials.gov Identifier:
NCT00955760
First received: August 6, 2009
Last updated: February 7, 2011
Last verified: August 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2009
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)